Editas Medicine, Inc. (EDIT) jumped 35.15 percent to $3.09, rising $0.80 on Wednesday, after Custom Market Insights released a report projecting strong growth in the synthetic biology market.
The stock opened at $2.45 and traded between $2.44 and $3.10, with 4.68 million shares changing hands compared to an average of 2.46 million on the Nasdaq. Editas Medicine's 52-week range is $0.91 to $4.19.
Industry experts highlighted increasing demand for sustainable solutions such as biofuels, biodegradable plastics, and eco-friendly chemicals, alongside advances in gene editing and biotechnology that could drive innovation in healthcare, agriculture, and industrial applications.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.